189 related articles for article (PubMed ID: 17168734)
1. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis.
Chakraborty G; Jain S; Behera R; Ahmed M; Sharma P; Kumar V; Kundu GC
Curr Mol Med; 2006 Dec; 6(8):819-30. PubMed ID: 17168734
[TBL] [Abstract][Full Text] [Related]
2. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms.
Chakraborty G; Jain S; Kundu GC
Cancer Res; 2008 Jan; 68(1):152-61. PubMed ID: 18172307
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin as a multifaceted driver of bone metastasis and drug resistance.
Pang X; Gong K; Zhang X; Wu S; Cui Y; Qian BZ
Pharmacol Res; 2019 Jun; 144():235-244. PubMed ID: 31028902
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin as a therapeutic target for cancer.
Bandopadhyay M; Bulbule A; Butti R; Chakraborty G; Ghorpade P; Ghosh P; Gorain M; Kale S; Kumar D; Kumar S; Totakura KV; Roy G; Sharma P; Shetti D; Soundararajan G; Thorat D; Tomar D; Nalukurthi R; Raja R; Mishra R; Yadav AS; Kundu GC
Expert Opin Ther Targets; 2014 Aug; 18(8):883-95. PubMed ID: 24899149
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis.
Raja R; Kale S; Thorat D; Soundararajan G; Lohite K; Mane A; Karnik S; Kundu GC
Oncogene; 2014 Apr; 33(16):2053-64. PubMed ID: 23728336
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via α9β1 integrin.
Kale S; Raja R; Thorat D; Soundararajan G; Patil TV; Kundu GC
Oncogene; 2014 May; 33(18):2295-306. PubMed ID: 23728342
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of stromal osteopontin in melanoma progression and metastasis.
Kumar S; Sharma P; Kumar D; Chakraborty G; Gorain M; Kundu GC
PLoS One; 2013; 8(7):e69116. PubMed ID: 23935934
[TBL] [Abstract][Full Text] [Related]
8. Role of osteopontin in cellular signaling and metastatic phenotype.
El-Tanani MK
Front Biosci; 2008 May; 13():4276-84. PubMed ID: 18508510
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin: role in cell signaling and cancer progression.
Rangaswami H; Bulbule A; Kundu GC
Trends Cell Biol; 2006 Feb; 16(2):79-87. PubMed ID: 16406521
[TBL] [Abstract][Full Text] [Related]
10. Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells.
Behera R; Kumar V; Lohite K; Karnik S; Kundu GC
Carcinogenesis; 2010 Feb; 31(2):192-200. PubMed ID: 19926637
[TBL] [Abstract][Full Text] [Related]
11. Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.
Das R; Philip S; Mahabeleshwar GH; Bulbule A; Kundu GC
IUBMB Life; 2005 Jun; 57(6):441-7. PubMed ID: 16012053
[TBL] [Abstract][Full Text] [Related]
12. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.
Mauri G; Jachetti E; Comuzzi B; Dugo M; Arioli I; Miotti S; Sangaletti S; Di Carlo E; Tripodo C; Colombo MP
Oncotarget; 2016 Jan; 7(4):3905-20. PubMed ID: 26700622
[TBL] [Abstract][Full Text] [Related]
13. Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice.
Cui R; Takahashi F; Ohashi R; Gu T; Yoshioka M; Nishio K; Ohe Y; Tominaga S; Takagi Y; Sasaki S; Fukuchi Y; Takahashi K
Lung Cancer; 2007 Sep; 57(3):302-10. PubMed ID: 17482311
[TBL] [Abstract][Full Text] [Related]
14. The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms.
Schulze EB; Hedley BD; Goodale D; Postenka CO; Al-Katib W; Tuck AB; Chambers AF; Allan AL
Breast Cancer Res Treat; 2008 Nov; 112(2):243-54. PubMed ID: 18097747
[TBL] [Abstract][Full Text] [Related]
15. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells.
Tilli TM; Mello KD; Ferreira LB; Matos AR; Accioly MT; Faria PA; Bellahcène A; Castronovo V; Gimba ER
Prostate; 2012 Nov; 72(15):1688-99. PubMed ID: 22495819
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin: an emerging therapeutic target for anticancer therapy.
Jain S; Chakraborty G; Bulbule A; Kaur R; Kundu GC
Expert Opin Ther Targets; 2007 Jan; 11(1):81-90. PubMed ID: 17150036
[TBL] [Abstract][Full Text] [Related]
17. Osteopontin: an effector and an effect of tumor metastasis.
Shevde LA; Das S; Clark DW; Samant RS
Curr Mol Med; 2010 Feb; 10(1):71-81. PubMed ID: 20205680
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435.
Shevde LA; Samant RS; Paik JC; Metge BJ; Chambers AF; Casey G; Frost AR; Welch DR
Clin Exp Metastasis; 2006; 23(2):123-33. PubMed ID: 16830223
[TBL] [Abstract][Full Text] [Related]
19. Osteopontin as a target for cancer therapy.
Johnston NI; Gunasekharan VK; Ravindranath A; O'Connell C; Johnston PG; El-Tanani MK
Front Biosci; 2008 May; 13():4361-72. PubMed ID: 18508515
[TBL] [Abstract][Full Text] [Related]
20. Osteopontin has a protective role in prostate tumor development in mice.
Danzaki K; Kanayama M; Alcazar O; Shinohara ML
Eur J Immunol; 2016 Nov; 46(11):2669-2678. PubMed ID: 27601131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
